USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: CREATIVE BIOMOLECULES, INC.
City: Hopkinton
State: MA
Zip+4: 01748
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $549,637.00 9
SBIR Phase II $760,000.00 2

Award List:

ENGINEERING OF ANTIBODY BINDING SITES TO TUMOR ANTIGENS

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: James S. Huston , Principal Investigator
Award Amount: $50,000.00

ENGINEERING OF ANTIBODY BINDING SITES TO TUMOR ANTIGENS

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: James S. Huston , Principal Investigator
Award Amount: $260,000.00
Abstract:
In this research, protein engineering is being utilized to generate the minimal combining site of antibodies, the so-called fv, which comprises vh and vl domains. in phase i we synthesized genes coding for the vh and vl domains of a specific antidigoxin antibody. the biosynthetic vh and vl are being… More

CARTILAGE MATRIX PROTECTION BY FORMS OF TIMP

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The goal of this research is to evaluate the role of metalloprotease inhibitors in controlling the pathological progression of joint diseases. in phase i, it is planned tocharacterize the ability of forms of tissue inhibitors of metalloproteinase to retard the breakdown of articular cartilage matrix… More

INTERACTIVE EFFECTS OF GROWTH FACTORS ON CARTILAGE

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The goal of this research is to elucidate the action of selected peptide growth factors on adult articular cartilage. bovine articular cartilage in serum-free organ culture will be used to evaluate the effect of selected growth factors, alone and in combinations, on chondrocyte matrix and dna… More

PDGF-AA-DIMER STRUCTURE AND ATHEROSCLEROSIS DRUG DESIGN

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: James Huston
Award Amount: $50,000.00
Abstract:
This project will develop the basis for structure analysis of pdgf-aa in phase i, leading to its 3-d structure determination in phase ii. the ultimate goal is to use the 3-d structure of pdgf to develop drugs that inhibit the actions of pdgf-aa in atherosclerosis. this approach will take advantage… More

HUMANIZED ANTITUMOR BINDING SITES: FRAMEWORK ENGINEERING

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Huston, James S , Principal Investigator
Award Amount: $50,000.00
Abstract:
Antibody variable (v) regions each comprise 3 complementary determining regions (cdrs) that form the antigen binding site and 4 framework regions (frs) that form the scaffold supporting the binding site. these segments are interspersed sequentially in each v region to form fr1-cdr-1… More

SINGLE-CHAIN FV-PEPTIDE FUSION INHIBITOR OF FIBRIN CLOTS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tai, Mei-sheng , Principal Investigator
Award Amount: $50,000.00
Abstract:
Given the major importance of cardiovascular drugs to public health in this country, it is remarkable that there are still no clinically effective agents that act directly on the fibrin during the clotting process. such drugs would hold the possibility of avoiding many of the side effects of heparin… More

GROWTH FACTOR REGENERATION OF PERIODONTAL TISSUE

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Charette, Marc F , Principal Investigator
Award Amount: $49,694.00

GROWTH FACTOR REGENERATION OF PERIODONTAL TISSUE

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Charette, Marc F , Principal Investigator
Award Amount: $500,000.00
Abstract:
The goal of this study is the regeneration of soft and hard tissue lost due to periodontal disease. this will be tested in phase i by: (1) formulation of biosynthetic human growth factors in a variety of delivery vehicles; (2) determination of bioavailability in vitro of growth factors in the… More

OP-1 3D STRUCTURE USED IN DRUG DESIGN FOR BONE DISORDERS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bosukonda, dattatreyamurt
Award Amount: $99,943.00

OP-1 TREATMENT FOR PARKINSONS DISEASE

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kaplan, Paul L
Award Amount: $100,000.00